The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Benfield, P., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632040-00002 · Cited by 494
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Self-citationEvidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.
Sesardic, D., Boobis, A., Murray, B., Murray, S., Segura, J., de la Torre, R., & Davies, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03686.x · Cited by 278
Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Säwe, J., & Villén, T. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.40 · Cited by 249
Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes-Jørgensen, T., Overø, K. F., & Gram, L. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00002 · Cited by 213
Self-citationThe relationship between paroxetine and the sparteine oxidation polymorphism
Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.23 · Cited by 205
Self-citationBr�sen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316471 · Cited by 193
Self-citationPharmacokinetics of Desipramine Coadministered With Sertraline or Fluoxetine
PRESKORN, S. H., ALDERMAN, J., CHUNG, M., HARRISON, W., MESSIG, M., & HARRIS, S. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00002 · Cited by 190
Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine
Vistisen, K., Poulsen, H. E., & Loft, S. (1992) · Carcinogenesis · doi:10.1093/carcin/13.9.1561 · Cited by 173
Self-citationSlow Omeprazole Metabolizers Are Also Poor S-Mephenytoin Hydroxylators
Andersson, T., Regårdh, C.-G., Dahl-Puustinen, M.-L., & Bertilsson, L. (1990) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199007000-00020 · Cited by 166
Elevated Levels of Clozapine in Serum After Addition of Fluvoxamine
HIEMKE, C., WEIGMANN, H., H??RTTER, S., DAHMEN, N., WETZEL, H., & M??LLER, H. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00011 · Cited by 163
Ward, S., Helsby, N., Skjelbo, E., Brosen, K., Gram, L., & Breckenridge, A. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05594.x · Cited by 163
Self-citationInhibitors of imipramine metabolism by human liver microsomes.
Skjelbo, E., & Brosen, K. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04133.x · Cited by 163
Rasmussen, B., Mäenpää, J., Pelkonen, O., Loft, S. H., Poulsen, H. E., Lykkesfeldt, J., & Brøsen, K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04422.x · Cited by 151
Self-citationSkjelbo, E., Brøsen, K., Hallas, J., et al. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.4 · Cited by 141
Self-citationEffect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects
Spina, E., Pollicino, A., Avenoso, A., Campo, G. M., Perucca, E., & Caputi, A. P. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199306000-00011 · Cited by 132
Sanz, E. J., Villén, T., Alm, C., et al. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.63 · Cited by 116
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*
Gram, L. F., Guentert, T. W., Grange, S., Vistisen, K. K., & Brøsen, K. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90230-9 · Cited by 100
Self-citationNielsen, K. K., Brøsen, K., Hansen, M. G. J., & Gram, L. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.65 · Cited by 91
Self-citationToxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy
Sperber, A. D. (1991) · Drug Safety · doi:10.2165/00002018-199106060-00006 · Cited by 89
Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes
Breyer-Pfaff, U., Pfandl, B., Nill, K., et al. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.155 · Cited by 88
Pato, M. T., Murphy, D. L., & DeVane, L. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00024 · Cited by 87
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation
Kupfer, A., & Branch, R. A. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.196 · Cited by 86
Fluvoxamine-tricyclic antidepressant interaction
Bertschy, G., Vandel, S., Vandel, B., Allers, G., & Volmat, R. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315151 · Cited by 85
Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients
Spina, E., Campo, G. M., Avenoso, A., et al. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199206000-00004 · Cited by 74
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drohse, A., Bathum, L., Brøsen, K., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03426.x · Cited by 32
Self-citation
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Metadata
- Authors
- Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1996-09-02
- Volume
- 51
- Issue
- 1
- Pages
- 73-78
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2045654730
- Cited by
- 321
- References
- 31
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.